Stay updated with breaking news from Nasdaq Bcli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock. Separately, Dawson James reiterated a “neutral” rating on shares of Brainstorm Cell Therapeutics in a report on Wednesday, December 22nd. […]
Brokerages expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) to post ($0.21) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. The lowest EPS estimate is ($0.29) and the highest is ($0.13). Brainstorm Cell Therapeutics posted earnings per share of ($0.19) during […]
StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) in a research report report published on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, Dawson James reissued a neutral rating on shares of Brainstorm Cell Therapeutics in a research note on Wednesday, December 22nd. NASDAQ:BCLI opened […]
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) released its earnings results on Monday. The biotechnology company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.03, Fidelity Earnings reports. During the same period in the prior year, the firm posted ($0.37) earnings per share. Shares of NASDAQ:BCLI traded up […]